TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)
Close on Nov 17, 2026Market cap $10.23MP/E –Yield –
TScan Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
TScan Therapeutics's enterprise value was -$43.27M on Nov 11, 2026, against -$10.49M a year earlier. Over the last 4 years it ranged from -$155.92M to $577.50M, with a median of -$9.55M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$43.27M | – |
| 2025 | Dec 31, 2025 | -$24.51M | -130.5% |
| 2024 | Dec 31, 2024 | $80.45M | -12.5% |
| 2023 | Dec 29, 2023 | $91.95M | – |
| 2022 | Jan 31, 2022 | -$153.99M | – |
| 2021 | Dec 31, 2021 | -$155.92M | – |
See a number that looks wrong?